Study finds weight-loss drug semaglutide may lower Alzheimer's risk in diabetes patients

A new study shows that semaglutide, found in weight-loss drugs like Ozempic and Wegovy, can significantly lower the risk of Alzheimer’s disease in people with type 2 diabetes. It reduces the risk of a first-time Alzheimer’s diagnosis by 40% to 70% compared to other diabetes medications. Researchers analyzed health records of over a million U.S. patients with type 2 diabetes. They found that those taking semaglutide had a notably lower risk of developing Alzheimer’s, especially compared to insulin users, who had a 70% higher risk. The study suggests that semaglutide may protect brain function by reducing inflammation and improving glucose use in brain cells. This research could lead to new treatment options for Alzheimer’s, particularly in countries like India, where diabetes rates are high.